

# CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity)

Submit an original, and a duplicate for processing.

(Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))

Docket No.

1038-746

☐ **DUPLICATE** (Check box if applicable)

First Named Inventor


Examiner

Group/Art Unit

Charles D.Y. Si

Robert D. Budens

RECEIVED



Address to:

Assistant Commissioner for Patents  
Box CPA  
Washington, D.C. 20231

JAN 05 2001

OFFICE OF PETITIONS

This is a request for filing a ☒ continuation, or ☐ divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 09/055744 filed on April 7, 1998 and entitled:

**HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES**

1. ☐ Enter the unentered amendment previously filed on \_\_\_\_\_ under 37 CFR 1.116 in the prior nonprovisional application.

2. ☒ A preliminary amendment is enclosed.

3. ☐ This application is being filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).

a. ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:

b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.

4. ☒ A new power of attorney or authorization of agent is enclosed.

5. ☒ An Information Disclosure Statement (IDS) is enclosed:

a. ☒ PTO-1449

b. ☒ Copies of IDS Citations

6. ☒ The fee for this application is calculated as follows:

## CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	15	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$80.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$710.00
TOTAL FILING FEE					\$710.00

01/04/2001 CNGUYEN 00000048 09055744

02 FEB 131 710.00

**CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity)**  
**(Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))**

☐ The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No.

- ☐ fees required under 37 C.F.R. 1.16.
- ☐ fees required under 37 C.F.R. 1.17.
- ☐ fees required under 37 C.F.R. 1.18.

**RECEIVED**

**JAN 05 2001**

**OFFICE OF PETITIONS**

8. ☒ A check in the amount of 710.00 is enclosed.

9. ☐ Also enclosed:

10. ☐ The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below:

**FINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity)**  
**(Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))**

RECEIVED

JAN 05 2001

**NOTES**

**Submit an original, and a duplicate for fee processing.**

OFFICE OF PETITIONS

**FILING QUALIFICATIONS:** The prior application must be a nonprovisional application that is either: (1) complete as defined by 37 C.F.R. 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 USC 154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

**C-I-P NOT PERMITTED:** A continuation-in-part application cannot be filed as a CPA under 37 C.F.R. 1.53(d), but must be filed under 37 C.F.R. 1.53(b).

**EXPRESS ABANDONMENT OF PRIOR APPLICATION:** The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 C.F.R. 1.53(b) must be used to file a continuation, divisional or continuation-in-part of an application that is not to be abandoned.

**ACCESS TO PRIOR APPLICATION:** The filing of this CPA will be construed to include a waiver of confidentiality by the Applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 C.F.R. 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or application in the file jacket.

**35 U.S.C. 120 STATEMENT:** In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 C.F.R. 1.78(a).

Dated: December 4, 2000



24223

PATENT TRADEMARK OFFICE

*Michael I. Stewart*  
Signature

Michael I. Stewart  
Typed or printed name

24,973  
Registration Number (if applicable)

- ☐ Inventor(s)  
☐ Assignee of complete interest  
☒ Attorney or agent of record

cc:

IN THE UNITED STATES PATENT AND TRADEMARKS OFFICE

Our Ref.: 1038-746 MIS:ja

In re patent application

No.: 09/055,744

Applicant: Charles D. Y. Sia et al.

Title: HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES

Filed: April 7, 1998

Group No.: 1648

Examiner: Robert D. Budens



RECEIVED

JAN 05 2001

OFFICE OF PETITIONS

January 2, 2001

PRELIMINARY AMENDMENT

The Commissioner of Patents  
and Trademarks,  
Box AF,  
Washington, D.C. 20231,  
U.S.A.

Dear Sir:

Please amend this application in the following manner:

In the Claims:

Cancel claims 2 and 7

Amend claims 4, 6, 7 and 12 as follows:

4. (Amended) The method of claim 1 [2] wherein said T-helper molecule is CLP-243 (SEQ ID NO:10).

6. (Twice Amended) The method of claim 1 wherein said T-cell inducing HIV molecule includes a peptide having an amino acid sequence which is that of [corresponding to] a portion of an HIV-1 antigen and containing at least one T-cell epitope.

7. (Twice Amended) The method of claim 5 wherein said peptide having an amino acid sequence which is that of a portion [corresponds to sequences] of the Rev protein of HIV-1.

Sub C1